| Project/Area Number |
60480321
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Tokyo Medical College |
|---|
Principal Investigator |
NIITSUMA Masayuki Tokyo medical College, Lecturer, 医学部, 講師 (70150662)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Harubumi Tokyo Medical College, Associate Professor, 医学部, 助教授 (20074768)
KAWAMURA Ichita Tokyo Medical College, Professor, 医学部, 教授 (70074599)
HAYATA Yoshihiro Tokyo Medical College, Professor, 医学部, 教授 (30074470)
|
|---|
| Project Period (FY) |
1985 – 1987
|
| Project Status |
Completed (Fiscal Year 1987)
|
| Budget Amount *help |
¥6,300,000 (Direct Cost: ¥6,300,000)
Fiscal Year 1987: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1986: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1985: ¥4,500,000 (Direct Cost: ¥4,500,000)
|
|---|
| Keywords | Monoclonal antibody / Tumor markers / Immunological eytology / Immunotherapy / 毒性 / 単クローン性抗体 / 肺癌 / 宿主浸潤細胞 / 補体依存性殺細胞効果 / 肺小細胞癌 |
|---|
| Research Abstract |
Tumor markers for the diagnosis of lung cancer were investigated. Adenocarcinoma of the lung showed high levels of SLX, CEA, and CA19-9, squamous cell carcinoma of the lung showed high levels of CEA, CA19-9 and SCC and small cell carcinoma of the lung showed high levels of NSE. These results indicated that the combination of tumor markers, SLX, CEA, CA19-9, SCC and NSE should be useful for the detsermination of the histologic type of lung cancer. In small cell carcinoma, there are many varieties of surface antigens,differing between cases or between primary tumors and metastatic lymph node involvement in the same indivisual. These results suggested that immunological characterization of small cell carcinoma cells should be helpful to investigate the resistance against anti-cancer drugs by recurrent or metastatic small cell carcinoma of the lung. Peripheral bolld lymphocytes from the patients with lung cancer have natural killer (NK) activiyty and killer activity against cultured lung cancer cells and these activities can be enhanced by Interleukin-2. These results suggested that the use of combination immunotherapy of monoclonal antibodies and biological response modifiers for the treatment of lung cancer holds significant potential advantages. Experiments concerning the toxicity of monoclonal antibodies in many animal models showed no severe side effects. These results indicate that monoclonal antibodies will be useful for the diagnosis and the treatment of lung cancer.
|
